Eyes will be on Eikon’s upcoming data readout for its toll-like receptors 7 and 8 (TLR7/8) co-agonist, as the company looks to buck the trend of recent clinical trial failures with candidates that ...

Additional clinical-stage programs, including a Phase 2/3 trial in advanced melanoma, underscore momentum across the company’s oncology pipeline The presentation, titled "TeLuRide-005: Phase II study ...

The London Stock Exchange Group has sunset its Eikon offering and subsequently withdrawn the platform it from its product offerings, WatersTechnology can confirm. A spokesperson for LSEG said that in ...

First safety-and-efficacy readout from selective PARP1 inhibitor EIK1003-001 New clinical trial collaboration and supply agreement with Merck First patient dosed in Phase 1/2 study of CNS-penetrant ...

(KRON) — A Bay Area biotech company that laid off dozens of people this week has blamed the job cuts on policies of the Trump administration. Eikon Therapeutics Inc. cut 55 jobs from its Millbrae ...

Palantir, the software company cofounded by Peter Thiel, is part of an effort by Elon Musk’s so-called Department of Government Efficiency (DOGE) to build a new “mega API” for accessing Internal ...

OpenAI has recently launched its Responses API, a sophisticated toolset designed to enhance the capabilities of AI agents. This innovative offering integrates features such as web search, file search, ...

Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with a $350.7 million series D to fuel its various clinical trials.

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. Traditionally, organizations have interacted with their data warehouses using direct ...